Clinical Trials Browser

NIH × Hodgkin Disease × Sirolimus × Clear all

NCT00973804 2019-12-17

Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders

Phase 1 Terminated

LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT01076543 2019-10-16

Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Phase 1/2 Completed

110 enrolled 17 charts

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01902160 2015-11-09

Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1 Completed

Hodgkin Disease

NCT00086840 2013-01-24

CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 2 Terminated

LymphoidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse